Peptides in the Limelight: US FDA May Ease Restrictions on Several Peptides The Dermatology Digest BPC 157: Miracle Healing Peptide or Hidden Danger? The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA takes first step in possible reversal of ban on some peptides The Washington Post The Peptide Craze Part 2: BPC 157, NAD and the Truth Behind the Longevity Molecule Hype